The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
A roundup of news from Australia (CSL’s Seqirus), China (Pfizer), The Netherlands (Roche), the UK (Eisai, GSK, AstraZeneca), and the US (BMS, Sanofi, Daiichi Sankyo, J&J).
Australia
Seqirus To Invest $584 M in Influenza Vaccine Mfg...
The latest on manufacturing and potential treatments for COVID-19 with news from Moderna, Eli Lilly and Company, AstraZeneca, the World Health Organization, and others.
Manufacturing and supply of COVID-19 vaccines and drugs
Moderna, EU in Supply...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, reported that they have submitted a request to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) of their mRNA vaccine candidate, BNT162b2, against...
Novartis has formed an exclusive worldwide license and collaboration agreement, in a deal worth up to $1.355 billion ($50 million upfront and $1.305 billion in milestones and other payments), with Mesoblast, a Melbourne, Australia-based developer...
Merck & Co has agreed to acquire OncoImmune, a Rockville, Maryland-based clinical-stage biopharmaceutical company with a drug to treat COVID-19 in Phase III development, in a $475-million deal.
OncoImmune recently announced positive findings...
Eli Lilly and Company and Precision BioSciences, a Durham, North Carolina-based genome-editing company, have formed a research collaboration and exclusive license agreement to develop potential therapies for genetic disorders, in a...
Emer Cooke, formerly Director with the World Health Organization, began her new role as Executive Director of the European Medicines Agency (EMA) last week (November 16, 2020). She succeeds Guido Rasi, who completed his second term as Executive...
The latest on manufacturing and potential treatments for COVID-19 with news from Bausch Health, Inovio, the FDA, Bharat Biotech, and the Medicines Patent Pool.
Manufacturing and supply of COVID-19 vaccines and drugs
Generics Companies in Pact...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have achieved the safety data milestone required by the US Food and Drug Administration (FDA) for submission of emergency use authorization (EUA) for their mRNA-based COVID-19...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, has reported positive interim efficacy data of its COVID-19 vaccine candidate, mRNA-1273, from a Phase III study, which found the vaccine...
Johnson & Johnson (J&J) has expanded its partnership with the US government through a joint commitment from both parties to provide an additional $1 billion ($604 million from J&J and $454 million from the US government) to fund ongoing...
CureVac, a Tubingen, Germany-based clinical-stage biopharmaceutical company developing messenger ribonucleic acid (mRNA) therapeutics, is finalizing an agreement with the European Commission (EC) to supply its COVID-19 vaccine, CVnCoV, and is...
Bristol-Myers Squibb (BMS) has completed its $13.1-billion acquisition of MyoKardia, a Brisbane, California-based clinical-stage biopharmaceutical company focused on cardiovascular diseases. BMS had announced the acquisition last month (October...
Mylan and Pfizer have completed their previously announced combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business, to form a new company, Viatris. The companies had announced the merger in July...
The latest on manufacturing and potential treatments for COVID-19 with news from CSL, Regeneron, Lilly, AstraZeneca, Novartis, GSK, Novavax, CSL, Moderna, and others.
Manufacturing and supply of COVID-19 vaccines and drugs
CSL Begins...
